Amyloid β-Peptide (12-28) (human)

Pricing Availability   Qty
Cat.No. 1894 - Amyloid b-peptide (12-28) (human) | Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys | CAS No. 107015-83-8
Description: Amyloid β-peptide; minimum required for binding to brain proteins
Datasheet
Citations
Reviews
Literature

Biological Activity

Amyloid β-peptide fragment; minimum section required to bind to brain proteins. Binds with high affinity to α7-nicotinic ACh receptors, and impairs memory retention following central administration in mice in vivo.

Technical Data

M. Wt 1955.2
Formula C89H135N25O25
Sequence VHHQKLVFFAEDVGSNK
Storage Desiccate at -20°C
CAS Number 107015-83-8
PubChem ID 24868224
InChI Key WOMPQPMHRDDZMP-IJBWYZRXSA-N
Smiles [H]N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 0.70 mg/ml in water

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Flood et al (1994) An amyloid β-protein fragment, A b[12-28], equipotent impairs post-training memory processing when injected into different limbic system structures. Brain Res. 663 271 PMID: 7874511

Freir and Herron (2003) Nicotine enhances the depressive actions of A β 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. J.Neurophysiol. 89 2917 PMID: 12611941

Ray et al (1998) Binding of amyloid b-protein to intracellular brain proteins in rat and human. Neurochem.Res. 23 1277 PMID: 9804283


If you know of a relevant reference for Amyloid β-Peptide (12-28) (human), please let us know.

View Related Products by Target

Keywords: Amyloid b-peptide (12-28) (human), Amyloid b-peptide (12-28) (human) supplier, Amyloid, β-peptide, beta-peptides, β-Amyloid, beta-Amyloid, b-amyloid, Precursor, Protein, APP, Secretase, beta-peptide, (12-28), (human), amyloidbeta, amyloidb, amyloidβ, Beta, Peptides, 1894, Tocris Bioscience

Citations for Amyloid β-Peptide (12-28) (human)

Citations are publications that use Tocris products.

Currently there are no citations for Amyloid β-Peptide (12-28) (human). Do you know of a great paper that uses Amyloid β-Peptide (12-28) (human) from Tocris? Please let us know.

Reviews for Amyloid β-Peptide (12-28) (human)

There are currently no reviews for this product. Be the first to review Amyloid β-Peptide (12-28) (human) and earn rewards!

Have you used Amyloid β-Peptide (12-28) (human)?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.